Effect of guided imagery on anxiety, muscle pain, and vital signs in patients with COVID-19: A randomized controlled trial

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Associated Data

Multimedia component 1 GUID: 1669E787-DC48-4D93-885D-BF42D1A5CC22 Multimedia component 2 GUID: EAC7756C-F4C8-42F4-9531-384B16D6642D Multimedia component 3 GUID: 01DD8CEF-CBFB-40B1-8B8D-9FCDEBBF795E

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Abstract

Background

COVID-19 can lead to anxiety due to its high mortality rate. Patients with COVID-19 may suffer from muscle pain. This study aimed to determine the effect of guided imagery on anxiety, muscle pain, and vital signs in patients with COVID-19.

Methods

110 patients with COVID-19 were recruited and randomly assigned to two control and intervention groups. Data were collected using the Spielberger Anxiety Inventory, the McGill Pain Questionnaire, and the Visual Analogue Scale. The intervention group received ten training sessions of guided imagery.

Results

Conclusions

Guided imagery as a cost-effective method of complementary medicine is recommended to manage anxiety and pain in patients with COVID-19.

Keywords: Guided imagery, Anxiety, Pain, COVID-19, Clinical trial

1. Introduction

In December 2019, a cluster of pneumonia cases of unknown causes emerged in Wuhan, China, with clinical symptoms similar to viral pneumonia [1]. The new viral pneumonia was named COVID-19 (Coronavirus Disease), which has spread from the People's Republic of China to almost all countries, and on January 30, 2020, the World Health Organization (WHO) declared that the outbreak constitutes a public health emergency of international concern [2]. The WHO recently classified six clinical syndromes associated with COVID-19, including uncomplicated disease, mild pneumonia, severe pneumonia, Acute Respiratory Distress Syndrome (ARDS), sepsis, and septic shock. In uncomplicated cases, sufferers may have nonspecific symptoms such as fever, cough, sore throat, nasal congestion, weakness, headache, and muscle pain [3]. Chen et al. (2020) found that patients with COVID-19 suffer from clinical manifestations of fever (83%), cough (82%), dyspnea (31%), muscle pain (11%), confusion (9%), headache (8%), sore throat (5%), rhinorrhea (4%), chest pain (2%), diarrhea (2%), and nausea/vomiting (1%) [4]. Pimentel et al. (2020), in a study on patients with COVID-19, showed that during the disease course, blood pressure and fever remained within the normal range, and heart and respiration rates increased, and oxygen saturation decreased [5]. Moreover, Han et al. (2020) indicated that 44% of COVID-19 patients had muscle pain [6]. Regarding the lack of effective treatment for COVID-19, supportive therapies are mostly used as treatments, including oxygen therapy, antiviral drugs, and corticosteroid therapy [7].

However, to increase patient safety and prevent cross-infection in infectious respiratory patients (such as influenza, COVID-19), the contact, airborne, and droplet precautions should be used, which preferably require an isolation room [8]. Therefore, these patients should be quarantined or isolated for treatment, and most of them experience post-isolation anxiety as the clinical symptoms appear [9]. In a study by Wang et al. (2020), 28.8% of patients reported moderate to severe anxiety [10]. Other causes of anxiety in COVID-19 patients include stigma, social isolation, fear of death, uncertainty throughout the disease crisis, and immunological mechanisms [11,12].

As a type of psychological stress, anxiety causes a series of physiological and endocrine events, and ultimately weakens the immune system [9]. Ongoing anxiety causes the body to increase metabolism and consume more oxygen. As a result, the body responds to anxiety by increasing the depth of respiration [13]. Failure to relieve the anxiety causes cardiac, pulmonary, gastrointestinal, endocrine, and immune complications, while effective management of the pain and anxiety speeds up patients' recovery [14].

There are appropriate treatment strategies to alleviate anxiety's physical and psychological symptoms, including pharmacological and non-pharmacological interventions [15]. Pharmacological intervention is often time-consuming, leads to adverse effects, and increases healthcare costs [16]. Therefore, using non-pharmacological intervention as a complementary and not an alternative method is recommended to be used. There are methods in complementary medicine through which nurses can help patients [17]. In this regard, relaxation techniques are the most important non-pharmacological pain management methods [18]. Relaxation can reduce muscle tension and the destructive physiological effects of stress, such as high blood pressure, tachycardia, and muscle spasm by balancing the anterior and posterior hypothalamus' function, reducing the activity of the sympathetic nervous system, and releasing catecholamines [19]. Relaxation is performed in various methods such as progressive muscle relaxation, meditation, rhythmic breathing, etc. [20]. In this regard, guided imagery as a technique of mind-body medicine is based on the interconnection between body and mind as they can influence and strengthen each other in causing illness or being healthy. In guided imagery, the brain activated in the same area when experiencing an event is re-activated. In other words, a person creates exactly a stream of thoughts through which he/she would able to see, hear, feel, or smell what he/she desires or imagines in his/her imagination at the time [16]. Guided imagery is a relaxation technique that focuses on pleasant mental events and images rather than stressful emotions [21]. In this method, the client is involved with mental imagery to the extent that the body responds to it as a real experience to cause profound physiological consequences [22]. This method, as a complementary medicine technique, can be learned through either an instructor or self-study materials and used in cases of pain and anxiety to reduce pain and psychological stress [16]. Regarding the high levels of anxiety in COVID-19 patients [9,10], they suffer from severe muscle pain [6] as both anxiety and muscle pain can cause hemodynamic instability, delay the patient's recovery, and put the patient at risk. As a result, effective complementary medicine techniques are needed to help these patients. Regarding that, it is the nurses' duty to implement complementary therapies. The use of relaxation techniques such as guided imagery can be easily taught and performed by nurses, and the patients can learn these methods and perform them independently. Most importantly, these measures can establish deeper communication between the nurse and the client. This study aimed to determine the effect of guided imagery on anxiety, muscle pain, and vital signs in patients with COVID-19. Our hypotheses were:

Patients who receive guided imagery will have greater reduction in pain intensity than patients in the control group.

Patients who receive guided imagery will have greater reduction in pain quality than patients in the control group.

The mean anxiety scores of the patients who receive guided imagery will be higher than patients in the control group.

Guided imagery may affect patients' vital signs.

2. Methods

2.1. Research design

A single-blinded, parallel, randomized controlled trial was designed to achieve the research objectives.

2.2. Participants

After obtaining approval from the Faculty Research Committee and the Ethics Committee of Urmia University of Medical Sciences (with the ethics number of IR.UMSU.REC.1399.102), the researcher first referred to the research setting (temporary accommodations for COVID-19 patients in Urmia) and then received permission from the authorities to conduct the study. Inclusion criteria consisted of (a) signing written informed consent, (b) being literate, being conscious and oriented to time, place, and person, (c) having no severe visual and auditory disorders, (d) having no mental disorders, (e) having no history of hospitalization with a diagnosis of COVID-19, (f) having an oxygen saturation level of above 90%, and (g) being in the 18–60 age range. Exclusion criteria consisted of (a) withdrawal from the study because of any reason, (b) having oxygen saturation level of below 90%, (c) being seriously ill for any reason (such as ARDS), (d) departure from the temporary accommodation or being transfer to the hospital, (e) being discharged with personal consent or death, and (f) performing any procedure out of the routine program.

Eligible patients were selected using convenience sampling, and written informed consent was then obtained from those who achieved the inclusion criteria. The sample size was calculated using STATA software (StataCorp LP, College Station, TX, USA). According to the study by Shamekhi et al. [23] in which the mean score and standard deviation in the intervention and control groups were 82.67 ± 14.03 and 90.17 ± 11.73, respectively. The minimum sample size for each group was calculated 48 patients, based on the confidence interval of 95% and the power of 80%. The final sample size was 55 patients for each group and 110 patients for both intervention and control groups to consider a 10% attrition rate.

n = ( Z 1 − α 2 + Z 1 − β ) 2 ( δ 1 2 + δ 2 2 ) ( μ 1 − μ 2 ) 2 n = ( 1.96 + 0.84 ) 2 ( 14.03 2 + 11.73 2 ) ( 90.17 − 82.67 ) 2 = 48

2.3. Intervention

The participants were randomly allocated to two groups of intervention and control. To this end, the sealed envelope system was utilized as a total of 110 cards were prepared, and the letter G (Guided imagery group) was written on half of the cards (n = 55), and the letters C (control group) was written on another half (n = 55). The cards were then mixed, and at the patient's bedside, one of the cards was randomly selected by the patients. Then they were divided into one of two groups based on the letter of the cards. In the first session and after observing safety points (hand washing and sanitizing before and after the guided imagery sessions) and using personal protective equipment (N95 respirator, and medical gloves, gown, disposable cap, and shoe cover), the researcher introduced himself to the patients and explained the study methodology and objective. Then written informed consent was taken from all the participants. Moreover, preliminary data, including demographic characteristics, vital signs, and oxygen saturation were collected in the first session, and the questionnaires were filled in by the participants in both intervention and control groups. The researcher also completed the vital signs flow sheet before the intervention. The researcher recruitment and randomization until the target sample size (n = 110) was reached in a month period. Recruitment started on June 15, 2020 and ended on July 07, 2020. Among 120 consecutive qualified patients, 5 patients declined to participate in the study, 3 patients did not meet the inclusion criteria and 2 patients were transferred to other medical centers due to exacerbation of the disease (see Fig. 1 ). The patients were placed in separate rooms to prevent the probability of data contamination between the two intervention and control groups. The staff was also justified in this regard. Patients in both groups received routine care. However, in the intervention group, guided imagery protocol was conducted under a psychiatrist's supervision. In the intervention group, in parallel with routine care, each patient attended ten sessions of guided imagery for five consecutive days, twice a day (once from 9:00 to 9:30 a.m. and once from 6:00 to 6:30 p.m.). In each session, five different audio tracks were administered by the nurse, and the patient listened to the instructional guided imagery audio tracks using a headphone for about 25 min. Each session had five different guided imagery audio tracks from other sessions. During each session, the patient closed his/her eyes, took deep breaths, and relaxed his/her muscles to keep completely calm. Then, he/she moved towards the relevant imagery using the mind power and imagination [24]. The research team provided adequate standard headphones to conduct the intervention. Prepared audio tracks [25], which contained guided imagery training for the power of mind and visualization to control horrific events, were approved by a psychiatrist and the Ethics Committee members. The researcher himself had also been trained in guided imagery by a psychiatrist. During each session, it was tried to reduce any distractions such as background noises and help the patients concentrate upon the intervention. In addition, all phases of the study were performed under the supervision of an infectious disease specialist to tackle the problems. After the completion of training sessions, the questionnaires and the vital signs flow sheet were completed again. Finally, the data obtained from the two groups were compared.

Fig. 1

Research flow diagram based on Consort statement 2010.

2.4. Data collection

In the present study, data collection tools consisted of the demographic questionnaire, the Spielberger State-Trait Anxiety Inventory (STAI), the Short-Form McGill Pain Questionnaire (SF-MPQ), the Visual Analogue Scale (VAS), and the Vital Signs Flow Sheet. The demographic questionnaire included age, gender, education, marital status, occupation, residence, and smoking.

The Spielberger State-Trait Anxiety Inventory (STAI) is a 40-item self-report tool and consists of two parts. The first part measures state anxiety and includes 20 questions. This part is scored on a 4-point Likert scale from “Not at all = 1″ to “Very much so = 4".The second part measures trait anxiety and also includes 20 questions. This part is also scored on a 4-point Likert scale from “Almost never = 1″ to “Almost always = 4". The overall score of each part ranges from 20 to 80, so that low scores indicate a mild form of anxiety, whereas median scores indicate a moderate form of anxiety, and high scores indicate a severe form of anxiety [26]. In the study by Spielberger et al. (1983), the Cronbach's alpha coefficient for the state and the trait anxiety scale was reported to be 0.92 and 0.90, respectively. Moreover, the test-retest coefficient for the state and the trait anxiety scale was reported to be 0.62 and 0.68, respectively [27]. In Iran, the validity of this questionnaire has been confirmed, and its internal consistency has been corroborated as having a Cronbach's alpha of .91 [28,29].

The Short-Form McGill Pain Questionnaire (SF-MPQ) is a shorter version of the original MPQ and was developed by Melzak in 1987 [30]. This tool is made up of 15 descriptors in two subscales (11 sensory; 4 affective), and the Pain Rating Index has six rank values (from “No pain” to “Excruciating.” This scale has been used in numerous studies for assessing different types of pain. Stephenson and Herman (2000) found a good correlation between the SF-MPQ and the original MPQ (r = 0.86). Moreover, for internal consistency reliability, they reported Cronbach's alpha of 0.90 [31]. In Iran, Khosravi et al. (2013) developed the Persian version of this questionnaire using the cross-cultural adaptation with preserving the original structure. They also confirmed its reliability with Cronbach's alpha of above 0.8 for overall and all subscales of the questionnaire [32].

The Visual Analogue Scale is a psychometric instrument used to measure pain intensity. This scale consists of a 100 mm horizontal line with the left side signifying “no pain = 0″ and the right side signifying “worst pain = 100". The participants were asked to mark a spot on the line indicating their current level of pain or report its numerical value to the researcher. The pain intensity was divided into three levels of mild (1–30), moderate (40–70), and severe pain (80–100). This scale has been widely used, and its validity and reliability have been confirmed in case of acute pain [33]. The scale's reliability was assessed using Cronbach's alpha, which was found to be 0.94 [34]. The CONSORT 2010 checklist was used to ensure quality reporting in this study [35] (see Supplementary File).

2.5. Statistical analysis

After data collection, the Shapiro-Wilk test was used to determine the normality of data distribution. The researcher who was blinded to the data, conducted the analysis. All data were entered into IBM SPSS Statistics for Windows, version 25 (IBM Corp., Armonk, N.Y., USA) and analyzed using descriptive (frequency and percentage for analyzing qualitative variables, mean and standard deviation for normal quantitative variables, and median and Interquartile Range for non-normal quantitative variables) and analytical statistics (Chi-square and Fisher's exact test for examining the group homogeneity). The independent-samples t-test was also used to compare the normally distributed parameters between the two groups. Finally, the paired-samples t-test was used for in-group comparisons of normally distributed parameters. All analyses were performed by a researcher who was blind to the data.

3. Results

The results showed no statistically significant difference between the two groups in terms of gender, education, marital status, employment, residence, and smoking (p > .05). However, there was a statistically significant difference in terms of age between the two groups (p = .01) ( Table 1 ).

Table 1

Comparison of demographic characteristics of the patients in the study groups.

VariableGroup Result
Control Intervention
n (%)n (%)
GenderMale32 (58.2)30 (54.5)x = .148
Female23 (41.8)25 (45.5)df = 1 a p-value = .701
Elementary4 (7.3)4 (7.3)
Secondary10 (18.2)13 (23.6)x = 4.055
Education levelHigh school12 (21.8)19 (34.5)df = 3
Higher education29 (52.7)19 (34.5) a p-value = .256
Marital statusSingle18 (32.7)13 (23.6) b p-value = .397
Married37 (67.3)42 (76.4)
OccupationEmployed35 (63.6)35 (63.6)x = .784
Unemployed18 (32.7)16 (29.1)df = 2
Inactive2 (3.6)4(7.3) a p-value = .676
ResidenceRural13 (23.6)18 (32.7)x = 1.123
Urban42 (76.4)37 (67.3)df = 1 a p-value = .289
SmokingYes32 (58.2)36 (65.5) b p-value = .278
No23 (41.8)19 (34.5)
Age ControlInterventiont = 2.610
Mean ± SD d Mean ± SDdf = 108
37.32 ± 11.1243.14 ± 12.22 c p-value = .010